127 related articles for article (PubMed ID: 34996539)
21. OCT of Outer Retinal Hyperreflectivity, Neovascularization, and Pigment in Macular Telangiectasia Type 2.
Krivosic V; Lavia C; Aubineau A; Tadayoni R; Gaudric A
Ophthalmol Retina; 2021 Jun; 5(6):562-570. PubMed ID: 32956858
[TBL] [Abstract][Full Text] [Related]
22. Subthreshold Micropulse Yellow Laser (577 nm) for Idiopathic Macular Telangiectasia Type 1 Resistant to Intravitreal Injection.
Kang YK; Park HS
Korean J Ophthalmol; 2020 Apr; 34(2):168-169. PubMed ID: 32233152
[No Abstract] [Full Text] [Related]
23. Optical coherence tomographic angiography in type 1 idiopathic macular telangiectasia.
Pappuru RR; Peguda HK; Dave VP
Clin Exp Optom; 2018 Jan; 101(1):143-144. PubMed ID: 28295586
[No Abstract] [Full Text] [Related]
24. Smokestack Leak from Retinal Neovascularization.
Verma S; Venkatesh P; Kumar V
Ophthalmol Retina; 2021 Feb; 5(2):177. PubMed ID: 33549203
[No Abstract] [Full Text] [Related]
25. High-Resolution OCT Angiography Features of an Early Type 3 Neovascularization.
Bacci T; Freund KB
Ophthalmology; 2020 Jul; 127(7):887. PubMed ID: 32564812
[No Abstract] [Full Text] [Related]
26. Fluorescein Angiography Versus Optical Coherence Tomography Angiography in Macular Telangiectasia Type I Treated With Bevacizumab Therapy.
Yannuzzi NA; Gregori NZ; Roisman L; Gupta N; Goldhagen BE; Goldhardt R
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):263-266. PubMed ID: 28297041
[TBL] [Abstract][Full Text] [Related]
27. QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY PARAMETER VARIATIONS AFTER TREATMENT OF MACULAR NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Arrigo A; Aragona E; Bordato A; Amato A; Borghesan F; Bandello F; Parodi MB
Retina; 2021 Jul; 41(7):1463-1469. PubMed ID: 33315820
[TBL] [Abstract][Full Text] [Related]
28. YOUNGEST REPORTED CASE OF MACULAR TELANGIECTASIA (MAC TEL) TYPE 2.
Rajesh B; Giridhar A
Retin Cases Brief Rep; 2018 Spring; 12(2):115-117. PubMed ID: 27685499
[TBL] [Abstract][Full Text] [Related]
29. A case of Leber's miliary aneurysms with diffuse peripheral retinal vascular sheathing.
Lee A; Baek J; Ra H
Indian J Ophthalmol; 2018 Oct; 66(10):1496-1498. PubMed ID: 30249852
[TBL] [Abstract][Full Text] [Related]
30. Retinal Exudates and Hemorrhages in a Survivor of Breast Cancer.
Moussa K; Kim J; Miller JB
JAMA Ophthalmol; 2019 Feb; 137(2):218-219. PubMed ID: 30489605
[No Abstract] [Full Text] [Related]
31. Multimodal Imaging of Macular Telangiectasia Type 2: Focus on Vascular Changes Using Optical Coherence Tomography Angiography.
Toto L; Di Antonio L; Mastropasqua R; Mattei PA; Carpineto P; Borrelli E; Rispoli M; Lumbroso B; Mastropasqua L
Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT268-76. PubMed ID: 27409482
[TBL] [Abstract][Full Text] [Related]
32. GENESIS OF RETINAL-CHOROIDAL ANASTOMOSIS IN MACULAR TELANGIECTASIA TYPE 2: A Longitudinal Analysis.
Breazzano MP; Yannuzzi LA; Spaide RF
Retina; 2021 Mar; 41(3):464-470. PubMed ID: 32976212
[TBL] [Abstract][Full Text] [Related]
33. HYPERREFLECTIVITY ON OPTICAL COHERENCE TOMOGRAPHY IN MACULAR TELANGIECTASIA TYPE 2.
Tzaridis S; Hess K; Heeren TFC; Bonelli R; Holz FG; Friedlander M
Retina; 2021 Jul; 41(7):1428-1437. PubMed ID: 33438900
[TBL] [Abstract][Full Text] [Related]
34. Refining Coats' disease by ultra-widefield imaging and optical coherence tomography angiography.
Rabiolo A; Marchese A; Sacconi R; Cicinelli MV; Grosso A; Querques L; Querques G; Bandello F
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1881-1890. PubMed ID: 28875282
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2.
Narayanan R; Chhablani J; Sinha M; Dave V; Tyagi M; Pappuru RR; Kuppermann BD
Retina; 2012; 32(10):2001-5. PubMed ID: 22990322
[TBL] [Abstract][Full Text] [Related]
36. I see a seashell in my right eye.
Rahimy E; Vander J
JAMA Ophthalmol; 2014 Dec; 132(12):1413. PubMed ID: 25321604
[No Abstract] [Full Text] [Related]
37. Relevance of multicolor imaging, its component channels, and fundus autofluorescence in describing macular telangiectasia type-2 (MacTel) lesion characteristics.
Chandran K; Giridhar A; Desai S; Gopalakrishnan M; Indu VP; Sivaprasad S
Indian J Ophthalmol; 2024 Jan; 72(Suppl 1):S125-S134. PubMed ID: 38131554
[TBL] [Abstract][Full Text] [Related]
38. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
Karasu B; Gunay BO
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
[TBL] [Abstract][Full Text] [Related]
39. Idiopathic macular telangiectasia type 2 (idiopathic juxtafoveolar retinal telangiectasis type 2A, Mac Tel 2).
Wu L; Evans T; Arevalo JF
Surv Ophthalmol; 2013; 58(6):536-59. PubMed ID: 24160729
[TBL] [Abstract][Full Text] [Related]
40. Full-thickness macular hole and macular telangiectasia in a child with Coats' disease.
Kumar V; Goel N; Ghosh B; Raina UK
Ophthalmic Surg Lasers Imaging; 2010 Dec; 41 Online():e1-3. PubMed ID: 21210570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
